Supplemental Figure 1

1. Supplemental Figure 1 Zn-BG A B BSO C Auranofin D carfilzomib

2. Supplemental Table1: Characteristics of CLL patients in this study; * status unknown

3. Supplemental Figure 2

4. Supplemental Figure 3 A B Control 1.0 mM AF, 24 h CLL, p=.005 150 NLC, p=ns CLL-7607 ) % 100 ( y t i l i b a i 50 V CLL-7620 0 Control 1.0 mMAF C 1.0 mM AF, 24 h y 0.2 t i l p=.005 p=ns i b a 0.0 i v n -0.2 i e g n -0.4 a h c -0.6 e v i t -0.8 a l e R -1.0 NLC CLL

5. Supplemental Table 2: Leukemia cell burden for individual TCL-1 mice pre- and post-treatment with 2 weeks of auranofin. Leukemia cell burden

6. Supplemental Table 3: Gene expression changes of the 39 most up and downregulated genes in primary CLL cells following treatment with 1.0 µM of AF for 8 hours

7. Supplemental Table 4: Ingenuity pathway analysis of the top 5 perturbed networks in Primary CLL cells treated with 1 µM of AF

8. Supplemental Figure 4

9. Supplemental Figure 5 Primary CLL B. A. MEC-1 C. D. MEC-1 Primary CLL

10. Supplemental Figure 6 MEC1 A - - + - - + + + 500 µM H2O2, 8 h 2.5 mM NAC, 8 h Nrf2 CHOP GRP78 CL. CASP3 β-Actin